Immunotherapy of Cancer: Volume 128

Immunotherapy of Cancer: Volume 128

Volume editor  , Volume editor 

Free delivery worldwide

Available. Dispatched from the UK in 1 business day
When will my order arrive?

Description

Immunotherapy of Cancer provides information on cancer research related to inflammation and immunity, containing outstanding reviews by experts in the field. It is suitable for researchers and students who have an interest in cancer immunobiology.
show more

Product details

  • Hardback | 392 pages
  • 152 x 229 x 22.86mm | 788g
  • Academic Press Inc
  • San Diego, United States
  • English
  • 0128023163
  • 9780128023167

Table of contents

1. The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy
Danny N. Khalil, Sadna BudhuhD, Billel Gasmi, Roberta Zappasodi, Daniel Hirschhorn-Cymerman, Tamar Plitt, Olivier De Henau, Dmitriy Zamarin, Rikke B. Holmgaard, Judith T. Murphy, Jedd D. Wolchok and Taha Merghoub
2. Immune Targeting of Tumor Epithelial-Mesenchymal Transition Via Brachyury-Based Vaccines
Claudia Palena and Duane H. Hamilton
3. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment
Katherine H. Parker , Daniel W. Beury and Suzanne Ostrand Rosenberg
4. Phagocytes as Corrupted Policemen in Cancer-Related Inflammation
Eduardo Bonavita, Maria Rosaria Galdiero, Sebastien Jaillon and Alberto Mantovani
5. Tumor-Elicited Inflammation and Colorectal Cancer
Kepeng Wang and Michael Karin
6. Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment
Aliyah M. Weinstein and Walter J. Storkus
7. The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds
Melanie R. Rutkowski, Nikolaos Svoronos, Alfredo Perales Puchalt and Jose R. Conejo-Garcia
8. Control of CD8 T-cell Infiltration into Tumors by Vasculature and Microenvironment
J. David Peske, Amber B. Woods, and Victor H. Engelhard
9. Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology
Xiaofei Yu, Chunqing Guo, Paul B. Fisher, John R. Subjeck and Xiang-Yang Wang
show more

Review quote

Praise for the Serial "This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences." --American Scientist "Excellent, highly informative, in-depth reviews...expertly written, up-to-date, and well-referenced." --Journal of Medicinal Chemistry "This is a series that has a long tradition of excellence in the field of cancer biology." --Doody's Publishing Reviews
show more

About Xiang-Yang Wang

Professor, Dept of Human & Molecular Genetics, Virginia Commonwealth University, USA; Associate Director, VCU Institute of Molecular Medicine, Virginia, USA. The Wang laboratory has a long-standing interest in understanding stress response and stress sensing molecules in regulation of inflammation, host immunity, and the pathogenesis of diseases, including cancer. Paul B. Fisher, M.Ph., Ph.D., is an accomplished molecular biologist investigating the mechanisms involved in cancer development and progression in order to define improved methods for cancer prevention, detection and therapy. Fisher pioneered a powerful technique to study gene expression in specific tissues or cell types known as subtraction hybridization, which he has used to identify genes involved in many important and medically relevant physiological processes including cancer, neurodegeneration and infectious diseases. Studies in his laboratory focus on understanding the molecular and biochemical reasons for cancer development with a specific focus on understanding how cancers spread, a process called metastasis. The ultimate aim is to use this collected knowledge to bring new, more effective prevention techniques, diagnostic approaches and therapies from the laboratory bench to the patient's bedside. This is epitomized by his studies involving mda-7/IL-24, a gene that was discovered in his laboratory and has displayed significant clinical efficacy in a phase 1 clinical trial when injected directly into advanced cancers using a form of viral gene therapy. Using a novel cancer terminator virus, Ad.5/3-CTV, that is designed to replicate only within cancer cells while delivering the immune-modulating and toxic mda-7/IL-24 gene, Fisher and his clinical colleagues are developing a clinical trial in patients with glioblastoma multiforme, the most common and deadly form of brain cancer. Fisher has been consistently funded by the National Institutes of Health (NIH) over the past 35 years and is among the top 5 percent of NIH funded investigators during this period. He has published over 500 primary papers and reviews, served on numerous NIH study sections and government and private grant review panels and has over 55 issued patents. He is the recipient of multiple National Cancer Institute (NCI) Program Project Grants; investigator initiated R01 grants from the NIH, NCI and National Institute of General Medical Sciences (NIGMS); private foundation grants from the National Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation; and an Institutional Research and Academic Career Development Award from the NIH focusing on preparing students from groups underrepresented in the sciences for research careers. Fisher is Professor and Chair of the Department of Human and Molecular Genetics at the Virginia Commonwealth University (VCU) School of Medicine, Founding Director of the VCU Institute of Molecular Medicine and Thelma Newmeyer Corman Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey Cancer Center.
show more